|ADAPT Act Would Promote New Drug Development|
New bipartisan legislation supported by IDSA would advance drug development by establishing a new limited population antibacterial and antifungal drug approval pathway for drugs to treat serious or life-threatening infections where there exists an unmet medical need.
|IDSA Journal Club|
This month’s studies investigating: Predicting Drug-Resistant Organisms in HCAP: Do We Always Need to Go Big?; Preventing Hepatic Decompensation in HIV-HCV Coinfected Individuals; Another Flu Shot Benefit: Meta-Analysis Suggests Reduction in Cardiovascular Events After Vaccination; Eradication of CRE Gastrointestinal Colonization with Oral Antibiotics; Is Amoxicillin Really Associated with Rash in Acute EBV Infection? |
Upcoming dates to remember
- The combined meeting of IDSA, SHEA, HIVMA, and PIDS, Oct. 8-12, 2014, in San Francisco. Stay tuned for more information at www.idweek.org.
Renew Your IDSA Membership!
Medical Scholars Program Deadline
Feb. 3, 2014
6th Annual IDSA Fellows In-Training Exam
Feb. 4-5, 2014
Joint Research Awards Application Deadline
Mar. 17, 2014
Society Awards Nomination Deadline
Apr. 1, 2014
HIVMA Leadership Awards Nomination Deadline
Apr. 15, 2014